Definium Therapeutics (NASDAQ:DFTX) Shares Gap Up – Still a Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s share price gapped up prior to trading on Monday . The stock had previously closed at $38.89, but opened at $43.53. Definium Therapeutics shares last traded at $41.30, with a volume of 1,762,185 shares.

Definium Therapeutics News Summary

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its second Phase 3 study of DT120 ODT met its primary endpoint, showing a statistically significant improvement in anxiety symptoms among patients with GAD. The successful result follows positive findings from an earlier late-stage study, providing additional support for the drug’s potential efficacy. Definium’s LSD-based drug lowers anxiety in second successful late-stage study
• Positive Sentiment: The company’s Panorama Phase 3 trial achieved its goal, with topline data indicating meaningful anxiety improvement. Investors are likely viewing the readout as an important step toward a potential regulatory submission for DT120 ODT. Definium Therapeutics Announces Positive Topline Results
• Positive Sentiment: Needham reaffirmed its Buy rating and set a $66 price target, while Royal Bank of Canada previously assigned an Outperform rating. The bullish analyst views add support to the positive market reaction. Definium Therapeutics Earns Outperform Rating
• Neutral Sentiment: Trading in DFTX was temporarily halted for pending news before the clinical announcement, reflecting heightened volatility around the Phase 3 disclosure. The company also scheduled a webcast to discuss the results. Definium to Discuss Topline Results
• Neutral Sentiment: Definium granted options covering 56,650 shares to three new employees. The grants may create limited future dilution but are primarily intended as hiring incentives. Definium Announces New Employee Inducement Grants

Wall Street Analysts Forecast Growth

DFTX has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and issued a $66.00 price target on shares of Definium Therapeutics in a report on Monday. Stifel Nicolaus boosted their price objective on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. Finally, Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $63.00.

Definium Therapeutics Stock Up 3.5%

The firm has a market capitalization of $5.41 billion, a price-to-earnings ratio of -11.73 and a beta of 2.23. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average price is $43.01 and its 200 day moving average price is $30.33.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, research analysts forecast that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other news, insider Matthew Wiley sold 2,867 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the transaction, the insider directly owned 174,633 shares of the company’s stock, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the completion of the transaction, the chief financial officer owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 67,119 shares of company stock worth $2,887,496 in the last 90 days. 2.40% of the stock is owned by company insiders.

Institutional Trading of Definium Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DFTX. Nykredit A S acquired a new stake in Definium Therapeutics during the second quarter valued at $45,000. Cerity Partners LLC raised its position in shares of Definium Therapeutics by 2.4% in the second quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after acquiring an additional 1,165 shares during the period. Creative Planning raised its position in shares of Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after acquiring an additional 1,655 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its position in shares of Definium Therapeutics by 10.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after acquiring an additional 2,079 shares during the period. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.